Results of a randomized phase IIb study estimating overall survival of pralatrexate versus erlotinib in platinum-pretreated NSCLC.

7554 Background: Pralatrexate (PDX) is a folate analog targeting dihydrofolate reductase. A previous phase I trial in heavily pretreated patients (pts) with advanced NSCLC reported a 10% overall re...